NR2B and NR2D subunits coassemble in cerebellar Golgi cells to form a distinct NMDA receptor subtype restricted to extrasynaptic sites.
NMDA receptors (NMDARs) are thought to be tetrameric assemblies composed of NR1 and at least one type of NR2 subunit. The identity of the NR2 subunit (NR2A, -B, -C, -D) is critical in determining many of the functional properties of the receptor, such as channel conductance and deactivation time. Further diversity may arise from coassembly of more than one type of NR2 subunit, if the resulting triheteromeric assembly (NR1 plus two types of NR2) displays distinct functional properties. We have used gene-ablated mice (NR2D -/-) to examine the effects of the NR2D subunit on NMDAR channels and NMDAR EPSCs in cerebellar Golgi cells. These cells are thought to express both NR2B and NR2D subunits, a combination that occurs widely in the developing nervous system. Our experiments provide direct evidence that the low conductance NMDAR channels in Golgi cells arise from diheteromeric NR1/NR2D assemblies. To investigate whether a functionally distinct triheteromeric assembly was also expressed, we analyzed the kinetic and pharmacological properties of single-channel currents in isolated extrasynaptic patches. We found that after the loss of the NR2D subunit, the properties of the 50 pS NMDAR channels were altered. This result is consistent with the presence of a triheteromeric assembly (NR1/NR2B/NR2D) in cells from wild-type mice. However, we could find no difference in the properties of NMDAR-mediated EPSCs between wild-type and NR2D subunit ablated mice. Our experiments suggest that although both diheteromeric and triheteromeric NR2D-containing receptors are expressed in cerebellar Golgi cells, neither receptor type participates in parallel fiber to Golgi cell synaptic transmission. The presence of the NR2D subunit within an assembly may therefore result in its restriction to extrasynaptic sites.
Brickley
Stephen G
SG
Department of Pharmacology, University College London, London WC1E 6BT, United Kingdom.
Misra
Charu
C
Mok
M H Selina
MH
Mishina
Masayoshi
M
Cull-Candy
Stuart G
SG
D000818:Animals; D002531:Cerebellum / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D019706:Excitatory Postsynaptic Potentials / Q000502:physiology; D066298:In Vitro Techniques; D007700:Kinetics; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D016202:N-Methylaspartate / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D018408:Patch-Clamp Techniques; D010880:Piperidines / Q000494:pharmacology; D021122:Protein Subunits / Q000378:metabolism; D016194:Receptors, N-Methyl-D-Aspartate / Q000819:agonists / Q000235:genetics / Q000378:metabolism*; D013569:Synapses / Q000378:metabolism
D018690:Excitatory Amino Acid Agonists; D018691:Excitatory Amino Acid Antagonists; C121001:NR2B NMDA receptor; C464436:NR2D NMDA receptor; D010880:Piperidines; D021122:Protein Subunits; D016194:Receptors, N-Methyl-D-Aspartate; D016202:N-Methylaspartate; C010739:ifenprodil